Marked reductions in bioactive insulin-like growth factor I (IGF-I) during hemodialysis

Growth Hormone and IGF Research

Volumn 20, Issue 2, 2010, Pages 156-161

  Ivarsen, Per ^a   Chen, Jian Wen ^a   Tietze, Ida ^a   Christiansen, Jens Sandahl ^a   Flyvbjerg, Allan ^a   Frystyk, Jan ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bioactive IGF I; Hemodialysis; Insulin like growth factor

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C;

ADULT; AGED; ARTERIAL BLOOD; ARTICLE; BIOLOGICAL ACTIVITY; CATABOLISM; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HORMONE PROTEIN COMPLEX; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; THERAPY EFFECT; VENOUS BLOOD;

ADULT; AGED; CELLS, CULTURED; DOWN-REGULATION; FEMALE; HUMAN GROWTH HORMONE; HUMANS; IMMUNOASSAY; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS; YOUNG ADULT;

EID: 77949658532     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2009.12.001     Document Type: Article

References (39)

1. Bossola M., Muscaritoli M., Tazza L., Giungi S., Tortorelli A., Rossi F.F., et al. Malnutrition in hemodialysis patients: what therapy?. Am. J. Kidney Dis. 2005, 46:371-386.
2. Mahan J.D., Warady B.A. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr. Nephrol. 2006, 21:917-930.
3. Rabkin R., Sun D.F., Chen Y., Tan J., Schaefer F. Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling. Pediatr. Nephrol. 2005, 20:313-318.
4. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16:3-34.
5. Frystyk J., Ivarsen P., Skjærbæk C., Flyvbjerg A., Pedersen E.B., Ørskov H. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int. 1999, 56:2076-2084.
6. Gutierrez A., Bergstrom J., Alvestrand A. Protein catabolism in sham-hemodialysis: the effect of different membranes. Clin. Nephrol. 1992, 38:20-29.
7. Ikizler T.A., Pupim L.B., Brouillette J.R., Levenhagen D.K., Farmer K., Hakim R.M., et al. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am. J. Physiol. Endocrinol. Metab. 2002, 282:E107-E116.
8. Lofberg E., Essen P., McNurlan M., Wernerman J., Garlick P., Anderstam B., et al. Effect of hemodialysis on protein synthesis. Clin. Nephrol. 2000, 54:284-294.
9. Rocco M.V., Dwyer J.T., Larive B., Greene T., Cockram D.B., Chumlea W.C., et al. The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: results of the HEMO study. Kidney Int. 2004, 65:2321-2334.
10. Feldt-Rasmussen B., Lange M., Sulowicz W., Gafter U., Lai K.N., Wiedemann J., et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J. Am. Soc. Nephrol. 2007, 18:2161-2171.
11. Jacob V., Le Carpentier J.E., Salzano S., Naylor V., Wild G., Brown C.B., et al. IGF-I, a marker of undernutrition in hemodialysis patients. Am. J. Clin. Nutr. 1990, 52:39-44.
12. Axelsson J., Qureshi A.R., Divino-Filho J.C., Barany P., Heimburger O., Lindholm B., et al. Are insulin-like growth factor and its binding proteins 1 and 3 clinically useful as markers of malnutrition, sarcopenia and inflammation in end-stage renal disease?. Eur. J. Clin. Nutr. 2006, 60:718-726.
13. Pupim L.B., Flakoll P.J., Brouillette J.R., Levenhagen D.K., Hakim R.M., Ikizler T.A. Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. J. Clin. Invest. 2002, 110:483-492.
14. Caufriez A., Abramowicz D., Vanherweghem J.L., Copinschi G. Insulin-like growth factor I values in patients on maintenance hemodialysis: relationship to growth hormone and albumin levels. J. Endocrinol. Invest. 1993, 16:691-696.
15. Bohe J., Joly M.O., Arkouche W., Laville M., Fouque D. Haemodialysis with the biocompatible high permeability AN-69 membrane does not alter plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3. Nephrol. Dial. Transpl. 2001, 16:590-594.
16. Lindgren B.F., Odar-Cederlof I., Ericsson F., Brismar K. Decreased bioavailability of insulin-like growth factor-I, a cause of catabolism in hemodialysis patients?. Growth Regul. 1996, 6:137-143.
17. Frystyk J., Dinesen B., Ørskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul. 1995, 5:169-176.
18. Frystyk J., Skjærbæk C., Dinesen B., Ørskov H. Free insulin-like growth factors (IGF-I and IGF-II] in human serum. FEBS Lett. 1994, 348:185-191.
19. Krassas G.E., Pontikides N., Kaltsas T., Dumas A., Frystyk J., Chen J.W., et al. Free and total insulin-like growth factor (IGF]-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J. Clin. Endocrinol. Metab. 2003, 88:132-135.
20. Frystyk J., Højlund K., Rasmussen K.N., Jorgensen S.P., Wildner-Christensen M., Ørskov H. Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum. J. Clin. Endocrinol. Metab. 2002, 87:260-266.
21. Chen J.W., Ledet T., Ørskov H., Jessen N., Lund S., Whittaker J., et al. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E1149-E1155.
22. Chen J.W., Nielsen M.F., Caumo A., Vilstrup H., Christiansen J.S., Frystyk J. Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis. Eur. J. Endocrinol. 2006, 155:285-292.
23. Chen J.W., Højlund K., Beck-Nielsen H., Sandahl C.J., Ørskov H., Frystyk J. Free rather than total circulating insulin-like growth factor-I determines the feedback on growth hormone release in normal subjects. J. Clin. Endocrinol. Metab. 2005, 90:366-371.
24. Schwalbe S.L., Betts P.R., Rayner P.H., Rudd B.T. Somatomedin in growth disorders and chronic renal insufficiency in children. Brit. Med. J. 1977, 1:679-682.
25. Phillips L.S., Kopple J.D. Circulating somatomedin activity and sulfate levels in adults with normal and impaired kidney function. Metabolism 1981, 30:1091-1095.
26. Blum W.F., Ranke M.B., Kietzmann K., Tonshoff B., Mehls O. Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia. Pediatr. Nephrol. 1991, 5:539-544.
27. Møller A.V., Jørgensen S.P., Chen J.W., Larnkjaer A., Ledet T., Flyvbjerg A., et al. Glycosaminoglycans increase levels of free and bioactive IGF-I in vitro. Eur. J. Endocrinol. 2006, 155:297-305.
28. Brismar K., Fernqvist-Forbes E., Wahren J., Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1], IGFBP-3, and IGF-I in insulin-dependent diabetes. J. Clin. Endocrinol. Metab. 1994, 79:872-888.
29. Frystyk J. Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm. IGF Res. 2004, 14:337-375.
30. Abe M., Kaizu K., Matsumoto K. Plasma insulin is removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose. Ther. Apher Dial. 2007, 11:280-287.
31. Lang C.H., Frost R.A. Role of growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins in the catabolic response to injury and infection. Curr. Opin. Clin. Nutr. Metab. Care 2002, 5:271-279.
32. Higuchi T., Yamamoto C., Kuno T., Okada K., Soma M., Fukuda N., et al. A comparison of bicarbonate hemodialysis, hemodiafiltration, and acetate-free biofiltration on cytokine production. Ther. Apher Dial. 2004, 8:460-467.
33. Singh N.P., Bansal R., Thakur A., Kohli R., Bansal R.C., Agarwal S.K. Effect of membrane composition on cytokine production and clinical symptoms during hemodialysis: a crossover study. Renal Fail. 2003, 25:419-430.
34. Carlstrom K., Pousette A., Stege R., Lindholm A. Serum hormone levels in men with end stage renal disease. Scand. J. Urol. Nephrol. 1990, 24:75-78.
35. Westwood M., Gibson J.M., White A. Purification and characterization of the insulin-like growth factor-binding protein-1 phosphoform found in normal plasma. Endocrinology 1997, 138:1130-1136.
36. Ørskov H., Hansen Aap., Hansen H.E., Alberti K.G.M.M., Noy G.A., Nosadini R. Acetate: inhibitor of growth Hormone hypersecretion in Diabetic and non-diabetic uremic subjects. Acta Endocrinol. Copenh. 1982, 99:551-558.
37. Schmitz O., Hansen Aap., Hansen H.E., Ørskov H. Inhibition of arginine- and hypoglycemia-induced growth hormone release by acetate in dialysed patients. Clin. Nephrol. 1982, 17:70-76.
38. Giustina A., Veldhuis J.D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev. 1998, 19:717-797.
39. Sanaka T., Shinobe M., Ando M., Hizuka N., Kawaguchi H., Nihei H. IGF-I as an early indicator of malnutrition in patients with end- stage renal disease. Nephron 1994, 67:73-81.